Navigation Links
Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
Date:3/12/2008

Restructured majority of convertible notes due June 2008

Reduced net operating expenses going forward

Projects Zevalin(R) net sales revenues of $15 million in 2008

SEATTLE, March 13 /PRNewswire-FirstCall/ -- Seattle-Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) today reported recent accomplishments and financial results for the quarter and twelve months ended December 31, 2007.

Recent Events

Announced completion of Zevalin(R) (Ibritumomab Tiuxetan) acquisition from Biogen Idec for an upfront payment of $10.1 million and initiated building Zevalin sales, marketing, and medical affairs infrastructure

Raised $14.8 million in aggregate gross proceeds through the issuance of common and preferred stock and warrants; raised $51.7 million in an offering of 9% Senior Convertible Notes due 2012; of which $16.2 million was used to induce the conversion of $21.5 million of outstanding Series A,B,C, and D convertible preferred securities to common stock

Restructured approximately 81 percent of the convertible notes due in June 2008, reducing total due in 2008 from $55.9 million to $10.7 million

Reduced expected net operating expenses by 35%, targeting $77 million in net cash operating expenses in 2008, by focusing resources on reaching $15 million in net Zevalin revenues, pursuing European marketing authorization (MAA) for XYOTAX (paclitaxel poliglumex, CT-2103), preparing for a potential U.S. marketing application (NDA) for pixantrone (BBR 2778) in 2009, and supporting the advancement of brostallicin

"Now that we have made significant progress on our strategy of simplifying our capital structure, reducing operating expenses, and shifting our resources to near-term o
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
2. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
3. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
4. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
5. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
6. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
7. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
8. Cell Therapeutics, Inc. Announces $6.5 Million Offering
9. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
10. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
11. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... Aliso Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Cut Pro X . Each preset contains 15 seconds of unique footage that users ... presets that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, ...
(Date:8/28/2015)... , ... August 29, 2015 , ... Rio Salado ... learning and the student experience as part of the EDUCAUSE - Next Generation Learning ... . , This is the third Breakthrough Models Incubator hosted by EDUCAUSE ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published ... maker Paul LaRocco has gone through to open a pizzeria in Westchester. Mr. LaRocco ... tends to take several months, but the current process, having already gone on for ...
(Date:8/28/2015)... ... , ... The 6th Annual Survivor in the City, Chicago silent auction ... accolade to its cadre of widespread support—an official letter of support and gratitude from ... medical community and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain ...
(Date:8/28/2015)... Chicago,IL (PRWEB) , ... August 28, 2015 , ... ... Stencils Device Library for documenting and diagramming network and data center assets and ... Manufacturer / Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... the verbal IQ levels of children exposed to the epilepsy drug ... to the drug.// ,The study was conducted in 249 children ... mothers with epilepsy and tests were performed on both the mother ... ,It was seen that 41 children exposed to valproic acid during ...
... condition, often present at birth. It is marked by a ... extreme cases, it can make the hip prone to dislocation.// ... strong independent indicator for the development of osteoarthritis (OA) of ... of the leading causes of disability among the elderly. In ...
... a recent study researchers focused on the use ... their impact on cholesterol and C-reactive protein levels. ... the liver that predicts inflammation in the arteries. ... important key to determining cardiovascular risk.,Researchers focused on ...
... worldwide. Problems with a patient's urethra causes urine ... heavy objects. Austrian researchers say // they are ... cells, which they say makes the treatment especially ... from a patient's arm, culture them for six ...
... disorder caused by abnormal surges in the electrical circuits of ... affect more than 2 million people worldwide. More than half ... medications. // ,Researchers now say that a new study ... compared to drug therapy when treating those with temporal lobe ...
... nearly 30 years worth of data on breast cancer patients ... stages of disease at diagnosis and those who are diagnosed ... the most likely to die from the disease. Black women ... white women, as are those whose tumors are negative for ...
Cached Medicine News:
(Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today announced ... Logo - ... "Our new corporate identity signifies our transformation into a ... predictive analytics platform for patent claim validity." ... of the proprietary AIA Shield™ platform, the Company commenced a ...
(Date:8/28/2015)... and PITTSBURGH , ... MYL ) today announced that its shareholders have ... (NYSE: PRGO ; TASE) and the related ... at an extraordinary general meeting of shareholders held ... votes cast at the extraordinary general meeting. In ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... THOUSAND OAKS, Calif., Sept. 14 Amgen (Nasdaq: ... Bank of America Merrill Lynch Global Healthcare Conference ... at 9:50 a.m. Greenwich Mean Time.  Amgen executives ... Willard Dere, M.D., senior vice president, International Chief ...
... Sept. 14 Praxis EMR has submitted its application to ... apply for HITECH certification in the country. Under the ARRA ... incentives if they can demonstrate "meaningful use" of a certified ... Department of Health and Human Services to test and certify ...
Cached Medicine Technology:Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference 2Praxis EMR Among First to Apply for HITECH Certification 2
... Testosterone, (17-Hydroxy-4-androstene-3-one), a C19 steroid, is one ... [1]. In postpubertal males, testosterone is secreted ... small amount derived from peripheral conversion of ... been estimated that over 50% of serum ...
... Thyroid-stimulating hormone (TSH) is a 32 kDa ... the anterior pituitary gland [1]. The structure ... of the pituitary and placental gonadotropins, consisting ... identical between these hormones and a unique ...
... Thyroxine (T4) is the primary active ... the thyroid gland [1]. T4 is synthesized ... iodide trapping by the follicular cells, (ii) ... substrate leading to formation of 3-monoiodotyrosine and ...
... primarily by 5-monodeioination of thyroxine (T4) in ... production occurs at a rate which is ... of T3 from the thyroid gland into ... to 80-100 micrograms/day for T4. In addition, ...
Medicine Products: